VEGF aptamer and microtubule inhibitor

This page covers all VEGF aptamer and microtubule inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF.

Targets

VEGF

Phase 3 pipeline (1)

• VB-111 + Paclitaxel · Vascular Biogenics Ltd. operating as VBL Therapeutics · Oncology
  VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.